Search

Your search keyword '"Huijgevoort, N.C. van"' showing total 5 results
Start Over Author "Huijgevoort, N.C. van" Search Limiters Full Text

Refine your results

5 results on '"Huijgevoort, N.C. van"'

1. Nationwide practice and outcomes of endoscopic biliary drainage in resectable pancreatic head and periampullary cancer

Author

Latenstein, A.E.J., Mackay, T.M., Huijgevoort, N.C. van, Bonsing, B.A., Bosscha, K., Hol, L., Bruno, M.J., Coolsen, M.M., Festen, S., Geenen, E.J.M. van, Koerkamp, B. Groot, Hemmink, G.J.M., Hingh, I. de, Kazemier, G., Lubbinge, H., Meijer, V.E. de, Molenaar, I.Q., Quispel, R., Santvoort, H.C. van, Seerden, T.C., Stommel, M.W.J., Venneman, N.G., Verdonk, R.C., Besselink, M.G.H., Hooft, Jeanin E. van, Latenstein, A.E.J., Mackay, T.M., Huijgevoort, N.C. van, Bonsing, B.A., Bosscha, K., Hol, L., Bruno, M.J., Coolsen, M.M., Festen, S., Geenen, E.J.M. van, Koerkamp, B. Groot, Hemmink, G.J.M., Hingh, I. de, Kazemier, G., Lubbinge, H., Meijer, V.E. de, Molenaar, I.Q., Quispel, R., Santvoort, H.C. van, Seerden, T.C., Stommel, M.W.J., Venneman, N.G., Verdonk, R.C., Besselink, M.G.H., and Hooft, Jeanin E. van

Abstract

Item does not contain fulltext, BACKGROUND: Guidelines advise self-expanding metal stents (SEMS) over plastic stents in preoperative endoscopic biliary drainage (EBD) for malignant extrahepatic biliary obstruction. This study aims to assess nationwide practice and outcomes. METHODS: Patients with pancreatic head and periampullary cancer who underwent EBD before pancreatoduodenectomy were included from the Dutch Pancreatic Cancer Audit (2017-2018). Multivariable logistic and linear regression models were performed. RESULTS: In total, 575/1056 patients (62.0%) underwent preoperative EBD: 246 SEMS (42.8%) and 329 plastic stents (57.2%). EBD-related complications were comparable between the groups (44/246 (17.9%) vs. 64/329 (19.5%), p = 0.607), including pancreatitis (22/246 (8.9%) vs. 25/329 (7.6%), p = 0.387). EBD-related cholangitis was reduced after SEMS placement (10/246 (4.1%) vs. 32/329 (9.7%), p = 0.043), which was confirmed in multivariable analysis (OR 0.36 95%CI 0.15-0.87, p = 0.023). Major postoperative complications did not differ (58/246 (23.6%) vs. 90/329 (27.4%), p = 0.316), whereas postoperative pancreatic fistula (24/246 (9.8%) vs. 61/329 (18.5%), p = 0.004; OR 0.50 95%CI 0.27-0.94, p = 0.031) and hospital stay (14.0 days vs. 17.4 days, p = 0.005; B 2.86 95%CI -5.16 to -0.57, p = 0.014) were less after SEMS placement. CONCLUSION: This study found that preoperative EBD frequently involved plastic stents. SEMS seemed associated with lower risks of cholangitis and less postoperative pancreatic fistula, but without an increased pancreatitis risk.

Published
2021

2. Nationwide practice and outcomes of endoscopic biliary drainage in resectable pancreatic head and periampullary cancer

Author

Latenstein, A.E.J., Mackay, T.M., Huijgevoort, N.C. van, Bonsing, B.A., Bosscha, K., Hol, L., Bruno, M.J., Coolsen, M.M., Festen, S., Geenen, E.J.M. van, Koerkamp, B. Groot, Hemmink, G.J.M., Hingh, I. de, Kazemier, G., Lubbinge, H., Meijer, V.E. de, Molenaar, I.Q., Quispel, R., Santvoort, H.C. van, Seerden, T.C., Stommel, M.W.J., Venneman, N.G., Verdonk, R.C., Besselink, M.G.H., Hooft, Jeanin E. van, Latenstein, A.E.J., Mackay, T.M., Huijgevoort, N.C. van, Bonsing, B.A., Bosscha, K., Hol, L., Bruno, M.J., Coolsen, M.M., Festen, S., Geenen, E.J.M. van, Koerkamp, B. Groot, Hemmink, G.J.M., Hingh, I. de, Kazemier, G., Lubbinge, H., Meijer, V.E. de, Molenaar, I.Q., Quispel, R., Santvoort, H.C. van, Seerden, T.C., Stommel, M.W.J., Venneman, N.G., Verdonk, R.C., Besselink, M.G.H., and Hooft, Jeanin E. van

Abstract

Contains fulltext : 235659.pdf (Publisher’s version ) (Open Access), BACKGROUND: Guidelines advise self-expanding metal stents (SEMS) over plastic stents in preoperative endoscopic biliary drainage (EBD) for malignant extrahepatic biliary obstruction. This study aims to assess nationwide practice and outcomes. METHODS: Patients with pancreatic head and periampullary cancer who underwent EBD before pancreatoduodenectomy were included from the Dutch Pancreatic Cancer Audit (2017-2018). Multivariable logistic and linear regression models were performed. RESULTS: In total, 575/1056 patients (62.0%) underwent preoperative EBD: 246 SEMS (42.8%) and 329 plastic stents (57.2%). EBD-related complications were comparable between the groups (44/246 (17.9%) vs. 64/329 (19.5%), p = 0.607), including pancreatitis (22/246 (8.9%) vs. 25/329 (7.6%), p = 0.387). EBD-related cholangitis was reduced after SEMS placement (10/246 (4.1%) vs. 32/329 (9.7%), p = 0.043), which was confirmed in multivariable analysis (OR 0.36 95%CI 0.15-0.87, p = 0.023). Major postoperative complications did not differ (58/246 (23.6%) vs. 90/329 (27.4%), p = 0.316), whereas postoperative pancreatic fistula (24/246 (9.8%) vs. 61/329 (18.5%), p = 0.004; OR 0.50 95%CI 0.27-0.94, p = 0.031) and hospital stay (14.0 days vs. 17.4 days, p = 0.005; B 2.86 95%CI -5.16 to -0.57, p = 0.014) were less after SEMS placement. CONCLUSION: This study found that preoperative EBD frequently involved plastic stents. SEMS seemed associated with lower risks of cholangitis and less postoperative pancreatic fistula, but without an increased pancreatitis risk.

Published
2021

3. Nationwide practice and outcomes of endoscopic biliary drainage in resectable pancreatic head and periampullary cancer

Author

Latenstein, A.E.J., Mackay, T.M., Huijgevoort, N.C. van, Bonsing, B.A., Bosscha, K., Hol, L., Bruno, M.J., Coolsen, M.M., Festen, S., Geenen, E.J.M. van, Koerkamp, B. Groot, Hemmink, G.J.M., Hingh, I. de, Kazemier, G., Lubbinge, H., Meijer, V.E. de, Molenaar, I.Q., Quispel, R., Santvoort, H.C. van, Seerden, T.C., Stommel, M.W.J., Venneman, N.G., Verdonk, R.C., Besselink, M.G.H., Hooft, Jeanin E. van, Latenstein, A.E.J., Mackay, T.M., Huijgevoort, N.C. van, Bonsing, B.A., Bosscha, K., Hol, L., Bruno, M.J., Coolsen, M.M., Festen, S., Geenen, E.J.M. van, Koerkamp, B. Groot, Hemmink, G.J.M., Hingh, I. de, Kazemier, G., Lubbinge, H., Meijer, V.E. de, Molenaar, I.Q., Quispel, R., Santvoort, H.C. van, Seerden, T.C., Stommel, M.W.J., Venneman, N.G., Verdonk, R.C., Besselink, M.G.H., and Hooft, Jeanin E. van

Abstract

Contains fulltext : 235659.pdf (Publisher’s version ) (Open Access), BACKGROUND: Guidelines advise self-expanding metal stents (SEMS) over plastic stents in preoperative endoscopic biliary drainage (EBD) for malignant extrahepatic biliary obstruction. This study aims to assess nationwide practice and outcomes. METHODS: Patients with pancreatic head and periampullary cancer who underwent EBD before pancreatoduodenectomy were included from the Dutch Pancreatic Cancer Audit (2017-2018). Multivariable logistic and linear regression models were performed. RESULTS: In total, 575/1056 patients (62.0%) underwent preoperative EBD: 246 SEMS (42.8%) and 329 plastic stents (57.2%). EBD-related complications were comparable between the groups (44/246 (17.9%) vs. 64/329 (19.5%), p = 0.607), including pancreatitis (22/246 (8.9%) vs. 25/329 (7.6%), p = 0.387). EBD-related cholangitis was reduced after SEMS placement (10/246 (4.1%) vs. 32/329 (9.7%), p = 0.043), which was confirmed in multivariable analysis (OR 0.36 95%CI 0.15-0.87, p = 0.023). Major postoperative complications did not differ (58/246 (23.6%) vs. 90/329 (27.4%), p = 0.316), whereas postoperative pancreatic fistula (24/246 (9.8%) vs. 61/329 (18.5%), p = 0.004; OR 0.50 95%CI 0.27-0.94, p = 0.031) and hospital stay (14.0 days vs. 17.4 days, p = 0.005; B 2.86 95%CI -5.16 to -0.57, p = 0.014) were less after SEMS placement. CONCLUSION: This study found that preoperative EBD frequently involved plastic stents. SEMS seemed associated with lower risks of cholangitis and less postoperative pancreatic fistula, but without an increased pancreatitis risk.

Published
2021

4. Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled trial

Author

Mackay, T.M., Smits, F.J., Latenstein, A.E.J., Bogte, A., Bonsing, B.A., Bos, H., Bosscha, K., Brosens, L.A.A., Hol, L., Busch, O.R., Creemers, G.J., Curvers, W.L., Dulk, M den, Dieren, S. van, Driel, L. van, Festen, S., Geenen, E.J.M. van, Geest, L.G. van der, Groot, D.J.A. de, Groot, J.W.B. de, Mohammad, N. Haj, Haberkorn, B.C.M., Haver, J.T., Harst, E, Hemmink, G.J.M., Hingh, I.H. de, Hoge, C., Homs, M.Y.V., Huijgevoort, N.C. van, Jacobs, M.M.E., Kerver, E.D., Liem, M.S., Los, M., Lubbinge, H., Luelmo, S.A.C., Meijer, V.E. de, Mekenkamp, L., Molenaar, I.Q., Oijen, M.G. van, Patijn, G.A., Quispel, R., Rijssen, L.B. van, Romkens, T.E.H., Santvoort, H.C. van, Schreinemakers, J.M.J., Schut, H., Seerden, T., Stommel, M.W., Tije, A.J. Ten, Venneman, N.G., Verdonk, R.C., Verheij, J., Vilsteren, F.G.I. van, Vos-Geelen, J. de, Vulink, A., Wientjes, C., Wit, F., Wessels, F.J., Zonderhuis, B., Werkhoven, C.H. van, Hooft, Jeanin E. van, Eijck, C.H. van, Wilmink, J.W., Laarhoven, H.W. van, Besselink, M.G.H., Mackay, T.M., Smits, F.J., Latenstein, A.E.J., Bogte, A., Bonsing, B.A., Bos, H., Bosscha, K., Brosens, L.A.A., Hol, L., Busch, O.R., Creemers, G.J., Curvers, W.L., Dulk, M den, Dieren, S. van, Driel, L. van, Festen, S., Geenen, E.J.M. van, Geest, L.G. van der, Groot, D.J.A. de, Groot, J.W.B. de, Mohammad, N. Haj, Haberkorn, B.C.M., Haver, J.T., Harst, E, Hemmink, G.J.M., Hingh, I.H. de, Hoge, C., Homs, M.Y.V., Huijgevoort, N.C. van, Jacobs, M.M.E., Kerver, E.D., Liem, M.S., Los, M., Lubbinge, H., Luelmo, S.A.C., Meijer, V.E. de, Mekenkamp, L., Molenaar, I.Q., Oijen, M.G. van, Patijn, G.A., Quispel, R., Rijssen, L.B. van, Romkens, T.E.H., Santvoort, H.C. van, Schreinemakers, J.M.J., Schut, H., Seerden, T., Stommel, M.W., Tije, A.J. Ten, Venneman, N.G., Verdonk, R.C., Verheij, J., Vilsteren, F.G.I. van, Vos-Geelen, J. de, Vulink, A., Wientjes, C., Wit, F., Wessels, F.J., Zonderhuis, B., Werkhoven, C.H. van, Hooft, Jeanin E. van, Eijck, C.H. van, Wilmink, J.W., Laarhoven, H.W. van, and Besselink, M.G.H.

Abstract

Contains fulltext : 225263.pdf (publisher's version ) (Open Access), BACKGROUND: Pancreatic cancer has a very poor prognosis. Best practices for the use of chemotherapy, enzyme replacement therapy, and biliary drainage have been identified but their implementation in daily clinical practice is often suboptimal. We hypothesized that a nationwide program to enhance implementation of these best practices in pancreatic cancer care would improve survival and quality of life. METHODS/DESIGN: PACAP-1 is a nationwide multicenter stepped-wedge cluster randomized controlled superiority trial. In a per-center stepwise and randomized manner, best practices in pancreatic cancer care regarding the use of (neo)adjuvant and palliative chemotherapy, pancreatic enzyme replacement therapy, and metal biliary stents are implemented in all 17 Dutch pancreatic centers and their regional referral networks during a 6-week initiation period. Per pancreatic center, one multidisciplinary team functions as reference for the other centers in the network. Key best practices were identified from the literature, 3 years of data from existing nationwide registries within the Dutch Pancreatic Cancer Project (PACAP), and national expert meetings. The best practices follow the Dutch guideline on pancreatic cancer and the current state of the literature, and can be executed within daily clinical practice. The implementation process includes monitoring, return visits, and provider feedback in combination with education and reminders. Patient outcomes and compliance are monitored within the PACAP registries. Primary outcome is 1-year overall survival (for all disease stages). Secondary outcomes include quality of life, 3- and 5-year overall survival, and guideline compliance. An improvement of 10% in 1-year overall survival is considered clinically relevant. A 25-month study duration was chosen, which provides 80% statistical power for a mortality reduction of 10.0% in the 17 pancreatic cancer centers, with a required sample size of 2142 patients, corresponding to a 6.6% m

Published
2020

5. Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled trial

Author

Mackay, T.M., Smits, F.J., Latenstein, A.E.J., Bogte, A., Bonsing, B.A., Bos, H., Bosscha, K., Brosens, L.A.A., Hol, L., Busch, O.R., Creemers, G.J., Curvers, W.L., Dulk, M den, Dieren, S. van, Driel, L. van, Festen, S., Geenen, E.J.M. van, Geest, L.G. van der, Groot, D.J.A. de, Groot, J.W.B. de, Mohammad, N. Haj, Haberkorn, B.C.M., Haver, J.T., Harst, E, Hemmink, G.J.M., Hingh, I.H. de, Hoge, C., Homs, M.Y.V., Huijgevoort, N.C. van, Jacobs, M.M.E., Kerver, E.D., Liem, M.S., Los, M., Lubbinge, H., Luelmo, S.A.C., Meijer, V.E. de, Mekenkamp, L., Molenaar, I.Q., Oijen, M.G. van, Patijn, G.A., Quispel, R., Rijssen, L.B. van, Romkens, T.E.H., Santvoort, H.C. van, Schreinemakers, J.M.J., Schut, H., Seerden, T., Stommel, M.W., Tije, A.J. Ten, Venneman, N.G., Verdonk, R.C., Verheij, J., Vilsteren, F.G.I. van, Vos-Geelen, J. de, Vulink, A., Wientjes, C., Wit, F., Wessels, F.J., Zonderhuis, B., Werkhoven, C.H. van, Hooft, Jeanin E. van, Eijck, C.H. van, Wilmink, J.W., Laarhoven, H.W. van, Besselink, M.G.H., Mackay, T.M., Smits, F.J., Latenstein, A.E.J., Bogte, A., Bonsing, B.A., Bos, H., Bosscha, K., Brosens, L.A.A., Hol, L., Busch, O.R., Creemers, G.J., Curvers, W.L., Dulk, M den, Dieren, S. van, Driel, L. van, Festen, S., Geenen, E.J.M. van, Geest, L.G. van der, Groot, D.J.A. de, Groot, J.W.B. de, Mohammad, N. Haj, Haberkorn, B.C.M., Haver, J.T., Harst, E, Hemmink, G.J.M., Hingh, I.H. de, Hoge, C., Homs, M.Y.V., Huijgevoort, N.C. van, Jacobs, M.M.E., Kerver, E.D., Liem, M.S., Los, M., Lubbinge, H., Luelmo, S.A.C., Meijer, V.E. de, Mekenkamp, L., Molenaar, I.Q., Oijen, M.G. van, Patijn, G.A., Quispel, R., Rijssen, L.B. van, Romkens, T.E.H., Santvoort, H.C. van, Schreinemakers, J.M.J., Schut, H., Seerden, T., Stommel, M.W., Tije, A.J. Ten, Venneman, N.G., Verdonk, R.C., Verheij, J., Vilsteren, F.G.I. van, Vos-Geelen, J. de, Vulink, A., Wientjes, C., Wit, F., Wessels, F.J., Zonderhuis, B., Werkhoven, C.H. van, Hooft, Jeanin E. van, Eijck, C.H. van, Wilmink, J.W., Laarhoven, H.W. van, and Besselink, M.G.H.

Abstract

Contains fulltext : 225263.pdf (publisher's version ) (Open Access), BACKGROUND: Pancreatic cancer has a very poor prognosis. Best practices for the use of chemotherapy, enzyme replacement therapy, and biliary drainage have been identified but their implementation in daily clinical practice is often suboptimal. We hypothesized that a nationwide program to enhance implementation of these best practices in pancreatic cancer care would improve survival and quality of life. METHODS/DESIGN: PACAP-1 is a nationwide multicenter stepped-wedge cluster randomized controlled superiority trial. In a per-center stepwise and randomized manner, best practices in pancreatic cancer care regarding the use of (neo)adjuvant and palliative chemotherapy, pancreatic enzyme replacement therapy, and metal biliary stents are implemented in all 17 Dutch pancreatic centers and their regional referral networks during a 6-week initiation period. Per pancreatic center, one multidisciplinary team functions as reference for the other centers in the network. Key best practices were identified from the literature, 3 years of data from existing nationwide registries within the Dutch Pancreatic Cancer Project (PACAP), and national expert meetings. The best practices follow the Dutch guideline on pancreatic cancer and the current state of the literature, and can be executed within daily clinical practice. The implementation process includes monitoring, return visits, and provider feedback in combination with education and reminders. Patient outcomes and compliance are monitored within the PACAP registries. Primary outcome is 1-year overall survival (for all disease stages). Secondary outcomes include quality of life, 3- and 5-year overall survival, and guideline compliance. An improvement of 10% in 1-year overall survival is considered clinically relevant. A 25-month study duration was chosen, which provides 80% statistical power for a mortality reduction of 10.0% in the 17 pancreatic cancer centers, with a required sample size of 2142 patients, corresponding to a 6.6% m

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results